Phaseline

Companies › Centessa Pharmaceuticals (UK)

Centessa Pharmaceuticals (UK): clinical trials, targets and expected readouts

4 active drug programs in 5 registered trials: 3 Phase 2, 2 Phase 1; Neurology, Other; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
ORX750–Phase 2Narcolepsy Type 1Dec 2026
cleminorexton
Orexin receptor agonist
HCRTPhase 2Narcolepsy Type 1Sep 2027
ORX489–Phase 1Healthy Adult Male and Female VolunteersJun 2027
ORX142 Tablets–Phase 1Excessive Daytime Sleepiness–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07096674ORX750Phase 2Narcolepsy Type 1NeurologyApr 2026
NCT07082829ORX142 TabletsPhase 1Excessive Daytime SleepinessNeurologyJun 2026
NCT06752668ORX750Phase 2Narcolepsy Type 1NeurologyDec 2026
NCT07413666ORX489Phase 1Healthy Adult Male and Female VolunteersOtherJun 2027
NCT07598708cleminorextonPhase 2Narcolepsy Type 1NeurologySep 2027

Targets

HCRT (1)

Companies with the same targets

Alkermes Takeda

Companies built like this

Arctic Therapeutics Sundance Biosciences Teikoku Pharma USA Gateway Institute for Brain Research GEN İlaç ve Sağlık Ürünleri A.Ş.

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.